Employees: 368
Size Senores Pharmaceuticals (SENORES.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $538M, the 824th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,093 on 18 Nov 2026.
Performance Over six months the shares gained 3.4%, against -16.7% for the median peer and +3.8% for the India market (cap-weighted) — 5th highest of 19 in its peer set.
Growth Revenue grew 39.7% over the last twelve months (peer median -1.0%); the operating margin is 24.3% (peer median 6.3%).
Valuation It trades at 32.2× forward earnings against a peer median of 11.3× (2nd most expensive of 9).
Capital Return on invested capital runs 0.2 points below its cost of capital (9.7% WACC).
Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹7.22B | ₹6.33B | ₹3.97B | ₹2.14B | ₹353M |
| Revenue growth | — | +59% | +86% | +506% | — |
| Gross profit | ₹2.96B | ₹2.07B | ₹1.21B | ₹541M | ₹160M |
| EBITDA | ₹2.13B | ₹1.68B | ₹888M | ₹411M | ₹127M |
| Net income | ₹1.33B | ₹1.15B | ₹586M | ₹315M | ₹84.3M |
| Free cash flow | n/a | -₹2.13B | -₹2.17B | -₹856M | -₹502M |
| Capital expenditure | n/a | ₹2.65B | ₹1.58B | ₹518M | ₹473M |
| Total debt | ₹4.17B | ₹3.42B | ₹3.15B | ₹2.58B | ₹626M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SENORES.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.8% | -7.2% | 6th lowest of 20 |
| 6-month return | +3.4% | -16.7% | 5th highest of 19 |
| Distance from 52-week high | -31.7% | -40.7% | 5th highest of 20 |
| Revenue growth (TTM) | +39.7% | -1.0% | 3rd highest of 19 |
| Operating margin | 24.3% | 6.3% | 3rd highest of 18 |
| Forward P/E | 32.2× | 11.3× | 2nd most expensive of 9 |
| ROIC minus cost of capital | -0.2 pp | -3.4 pp | 6th highest of 16 |
| EV / EBITDA | 25.3× | 7.9× | most expensive of 6 |
| Net debt / EBITDA | 1.5× | 0.3× | 3rd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Senores Pharmaceuticals SENORES.NS | India | $538M | +3% | +40% | 24% | 32.2× | n/a | n/a |
| Morepen Laboratories MOREPENLAB.NS | India | $542M | +121% | +30% | 11% | n/a | n/a | n/a |
| Chimin Health Management 603222.SS | China | $533M | -31% | +1% | -28% | n/a | n/a | n/a |
| Electra Therapeutics ETRA | United States | $530M | n/a | n/a | n/a | n/a | n/a | n/a |
| Jinling Pharmaceutical 000919.SZ | China | $529M | -15% | -8% | 1% | n/a | 2.4% | +5.0% |
| Supriya Lifescience SUPRIYA.NS | India | $529M | -15% | +23% | 26% | 36.2× | 28.2% | +15.8% |
| Evonile Pharma EVONILE.NS | India | $529M | n/a | -5% | 12% | n/a | 49.3% | -1.5% |
| Jinhe Biotechnology 002688.SZ | China | $550M | -19% | +7% | 5% | 8.9× | 1.0% | +9.7% |
| Zeria Pharmaceutical 4559.T | Japan | $552M | -12% | +12% | 15% | 9.6× | -12.3% | +11.1% |
| Zevra Therapeutics ZVRA | United States | $552M | -9% | +75% | 31% | 11.3× | -4.9% | +51.6% |
| Boryung 003850.KS | South Korea | $554M | -13% | +6% | 6% | 11.3× | -3.1% | +12.6% |
| Aclaris Therapeutics ACRS | United States | $555M | -23% | -59% | -1,412% | n/a | n/a | n/a |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $557M | -24% | -3% | 7% | 9.0× | -5.8% | +4.1% |
| Beijing Science Sun Pharmaceutical 300485.SZ | China | $517M | -29% | -11% | -8% | n/a | n/a | n/a |
| Zhong Zhu Healthcare 600568.SS | China | $562M | -22% | -6% | -34% | n/a | n/a | n/a |
| Jenkem Technology 688356.SS | China | $563M | -30% | +52% | 11% | 30.2× | 36.4% | +11.2% |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $513M | -22% | -8% | 16% | n/a | -6.1% | +9.6% |
| Entera Bio ENTX | United States | $568M | +163% | -100% | n/a | n/a | n/a | n/a |
| Alumis ALMS | United States | $569M | -80% | -67% | -5,375% | n/a | n/a | n/a |
| Egetis Therapeutics EGTX.ST | Sweden | $509M | +76% | +27% | -645% | 15.1× | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $505M | +147% | n/a | n/a | n/a | n/a | n/a |